Flexion Therapeutics Executives
Flexion Therapeutics employs about 257 people. The company is managed by 21 executives with a total tenure of roughly 172 years, averaging almost 8.0 years of service per executive, having 12.24 employees per reported executive. Analysis of Flexion Therapeutics' management performance can provide insight into the firm performance.
| Michael Clayman CEO CEO, Co-Founder, Board Member |
| Patrick Mahaffy Chairman Chairman of the Board |
Flexion |
Flexion Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (18.99) % which means that it has lost $18.99 on every $100 spent on assets. This is way below average. Flexion Therapeutics' management efficiency ratios could be used to measure how well Flexion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Flexion Therapeutics Workforce Comparison
Flexion Therapeutics is one of the top stocks in number of employees category among related companies. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 5,696. Flexion Therapeutics holds roughly 257 in number of employees claiming about 5% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of (92.52) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (71.24) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $71.24. Flexion Therapeutics Notable Stakeholders
A Flexion Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Flexion Therapeutics often face trade-offs trying to please all of them. Flexion Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Flexion Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Neil Bodick | Chief Medical Officer & Co-Founder | Profile | |
| Michael Clayman | CEO, Co-Founder, Board Member | Profile | |
| Patrick Mahaffy | Chairman of the Board | Profile | |
| Mark Levine | Senior Vice President General Counsel, Secretary | Profile | |
| Dan Thornton | Vice President - Market Access | Profile | |
| John Magee | Vice President - Sales | Profile | |
| Mark Fraga | Vice President - Marketing | Profile | |
| Scott Kelley | Vice President - Medical Affairs | Profile | |
| David Arkowitz | CFO, Principal Financial Officer and Principal Accounting Officer | Profile | |
| Frederick Driscoll | CFO and Principal Accounting Officer | Profile | |
| Sandesh Mahatme | Director | Profile | |
| Scott Canute | Director | Profile | |
| Ann Merrifield | Director | Profile | |
| Alan Milinazzo | Independent Director | Profile | |
| Heath Lukatch | Independent Director | Profile | |
| Samuel Colella | Independent Director | Profile | |
| Mark Stejbach | Director | Profile | |
| Jon Mahlowitz | VP of Legal Affairs | Profile | |
| Kerry Wentworth | Chief Regulatory Officer | Profile | |
| Christina Willwerth | Chief Strategy Officer | Profile | |
| Yamo Deniz | Chief Medical Officer | Profile |
Flexion Therapeutics Workforce Analysis
Traditionally, organizations such as Flexion Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Flexion Therapeutics within its industry.Flexion Therapeutics Manpower Efficiency
Return on Flexion Therapeutics Manpower
| Revenue Per Employee | 399.8K | |
| Revenue Per Executive | 4.9M | |
| Net Loss Per Employee | 369.8K | |
| Net Loss Per Executive | 4.5M | |
| Working Capital Per Employee | 404.8K | |
| Working Capital Per Executive | 5M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Flexion Stock
If you are still planning to invest in Flexion Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Flexion Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |